WO2022219652A1 - Novel sublingual pharmaceutical formulations for everolimus - Google Patents
Novel sublingual pharmaceutical formulations for everolimus Download PDFInfo
- Publication number
- WO2022219652A1 WO2022219652A1 PCT/IN2022/050364 IN2022050364W WO2022219652A1 WO 2022219652 A1 WO2022219652 A1 WO 2022219652A1 IN 2022050364 W IN2022050364 W IN 2022050364W WO 2022219652 A1 WO2022219652 A1 WO 2022219652A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- everolimus
- present
- composition
- pharmaceutical composition
- sublingual
- Prior art date
Links
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 title claims abstract description 88
- 229960005167 everolimus Drugs 0.000 title claims abstract description 77
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 30
- 239000000203 mixture Substances 0.000 claims description 68
- 239000002904 solvent Substances 0.000 claims description 16
- 239000003963 antioxidant agent Substances 0.000 claims description 11
- 235000006708 antioxidants Nutrition 0.000 claims description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 10
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims description 10
- 239000000314 lubricant Substances 0.000 claims description 9
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims description 8
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical group CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 8
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 8
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims description 8
- 229940095259 butylated hydroxytoluene Drugs 0.000 claims description 8
- 239000007884 disintegrant Substances 0.000 claims description 8
- 239000004376 Sucralose Substances 0.000 claims description 6
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 6
- 239000000796 flavoring agent Substances 0.000 claims description 6
- 235000013355 food flavoring agent Nutrition 0.000 claims description 6
- 229920001993 poloxamer 188 Polymers 0.000 claims description 6
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 6
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 6
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 6
- 235000019408 sucralose Nutrition 0.000 claims description 6
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 4
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 claims description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 4
- 230000003078 antioxidant effect Effects 0.000 claims description 4
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 4
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 4
- 229940044519 poloxamer 188 Drugs 0.000 claims description 4
- 239000004141 Sodium laurylsulphate Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 abstract description 17
- 150000003839 salts Chemical class 0.000 abstract description 13
- 239000006190 sub-lingual tablet Substances 0.000 abstract description 12
- 230000035699 permeability Effects 0.000 abstract description 9
- 238000000034 method Methods 0.000 abstract description 8
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- 230000008569 process Effects 0.000 abstract description 6
- 239000003826 tablet Substances 0.000 description 24
- 239000000546 pharmaceutical excipient Substances 0.000 description 21
- 238000009472 formulation Methods 0.000 description 18
- 238000004090 dissolution Methods 0.000 description 15
- -1 b-carotenes Chemical compound 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 239000008187 granular material Substances 0.000 description 13
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 11
- 239000011230 binding agent Substances 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 229960000913 crospovidone Drugs 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 10
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 10
- 229940098466 sublingual tablet Drugs 0.000 description 10
- 235000014113 dietary fatty acids Nutrition 0.000 description 8
- 239000000194 fatty acid Substances 0.000 description 8
- 229930195729 fatty acid Natural products 0.000 description 8
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 230000002195 synergetic effect Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 229930195725 Mannitol Natural products 0.000 description 6
- 238000005461 lubrication Methods 0.000 description 6
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- 239000000594 mannitol Substances 0.000 description 6
- 235000010355 mannitol Nutrition 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 229960002930 sirolimus Drugs 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000005550 wet granulation Methods 0.000 description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 4
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 4
- 229940042992 afinitor Drugs 0.000 description 4
- 238000007906 compression Methods 0.000 description 4
- 230000006835 compression Effects 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 239000005414 inactive ingredient Substances 0.000 description 4
- 229960001855 mannitol Drugs 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000007968 orange flavor Substances 0.000 description 4
- 229920001983 poloxamer Polymers 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- 229940043785 zortress Drugs 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 102100033757 Acyl-coenzyme A thioesterase 11 Human genes 0.000 description 3
- 101710169763 Acyl-coenzyme A thioesterase 11 Proteins 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000007919 dispersible tablet Substances 0.000 description 3
- 239000012738 dissolution medium Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 238000010579 first pass effect Methods 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 3
- 229920003109 sodium starch glycolate Polymers 0.000 description 3
- 229940079832 sodium starch glycolate Drugs 0.000 description 3
- 239000008109 sodium starch glycolate Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010003571 Astrocytoma Diseases 0.000 description 2
- 206010065869 Astrocytoma, low grade Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 239000001692 EU approved anti-caking agent Substances 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- 229940124639 Selective inhibitor Drugs 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 208000026911 Tuberous sclerosis complex Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 229960003943 hypromellose Drugs 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229960001021 lactose monohydrate Drugs 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 229940057948 magnesium stearate Drugs 0.000 description 2
- 239000007935 oral tablet Substances 0.000 description 2
- 229940096978 oral tablet Drugs 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 239000007962 solid dispersion Substances 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 201000004059 subependymal giant cell astrocytoma Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000007940 sugar coated tablet Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 208000009999 tuberous sclerosis Diseases 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229920001908 Hydrogenated starch hydrolysate Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 206010028034 Mouth ulceration Diseases 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 201000010927 Mucositis Diseases 0.000 description 1
- FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000007117 Oral Ulcer Diseases 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 229960004977 anhydrous lactose Drugs 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229960002798 cetrimide Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- JAUGGEIKQIHSMF-UHFFFAOYSA-N dialuminum;dimagnesium;dioxido(oxo)silane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O JAUGGEIKQIHSMF-UHFFFAOYSA-N 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000009474 immediate action Effects 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 239000000905 isomalt Substances 0.000 description 1
- 235000010439 isomalt Nutrition 0.000 description 1
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- LPHFLPKXBKBHRW-UHFFFAOYSA-L magnesium;hydrogen sulfite Chemical compound [Mg+2].OS([O-])=O.OS([O-])=O LPHFLPKXBKBHRW-UHFFFAOYSA-L 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 229940100692 oral suspension Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 150000003235 pyrrolidines Chemical class 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000004289 sodium hydrogen sulphite Substances 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 230000003746 surface roughness Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940040064 ubiquinol Drugs 0.000 description 1
- QNTNKSLOFHEFPK-UPTCCGCDSA-N ubiquinol-10 Chemical compound COC1=C(O)C(C)=C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)C(O)=C1OC QNTNKSLOFHEFPK-UPTCCGCDSA-N 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 239000008371 vanilla flavor Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000002888 zwitterionic surfactant Substances 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Definitions
- the present invention relates to novel sublingual pharmaceutical formulations of Everolimus and pharmaceutically acceptable salt thereof.
- This present invention discloses sublingual tablet compositions of Everolimus and pharmaceutically acceptable salt thereof using one or more pharmaceutically acceptable excipients.
- the present invention relates to providing an economical, patient compliant and technically advanced dosage form over existing dosage forms.
- the present invention shows industrial applicability in present industry infrastructure because it involves manufacturing of a tablet dosage form, which requires routine machineries.
- Everolimus (CAS: 159351 -69-6) is a macrocyclic lactone that is rapamycin in which the hydroxy group attached to the cyclohexyl moiety has been converted into the corresponding 2-hydroxyethyl ether.
- Everolimus is chemically known as (1 R,9S,12S,15R,16E,18R,19R,21 R,23S,24E, 26E,28E,30S,32S,35R)-1 ,18-dihydroxy- 12- ⁇ (1 R)-2-[(1 S,3R,4R)-4-(2-hydroxy- ethoxy)-3-methoxycyclohexyl]-1 -methylethyl ⁇ -19,30-dimethoxy-15,17,21 ,23,29, 35-hexamethyl-11 ,36-dioxa-4-aza-tricyclo[30.3.1 .0]hexatriaconta-16,24,26,28- tetraene-2,3,10,14,20-pentaone and is represented structurally as below: EVEROLIMUS (I)
- Everolimus the 40-O-(2-hydroxyethyl) derivative of rapamycin (sirolimus), is a potent and selective inhibitor of mammalian target of rapamycin (mTOR).
- mTOR mammalian target of rapamycin
- Everolimus is selective for the mTORCI protein complex.
- Everolimus exhibits potent immunosuppressive and anticancer activities.
- Everolimus is a white to beige colored powder with an empirical formula of C53FI83NO14 and the molecular weight is 958.2.
- US5665772 discloses O-alkylated rapamycin derivatives which covers Everolimus for the first time.
- Everolimus is marketed as tablets (AFINITOR ® and Zortress ® ), and tablets for oral suspension (AFINITOR DISPERZ ® ) by Novartis in USA.
- AFINITOR ® tablets are approved by the United States Food and Drug Administration (USFDA) as anticancer agent in the treatment of advanced renal cell carcinoma (RCC) and subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis (TS).
- USFDA United States Food and Drug Administration
- SEGA subependymal giant cell astrocytoma
- TS tuberous sclerosis
- Zortress ® tablets are approved by USFDA as immunosuppressant agent in the treatment of Prophylaxis of organ rejection in adult patients.
- Both AFINITOR ® and Zortress ® tablets contain lactose monohydrate, crospovidone, butylated hydroxytoluene (BFIT), hypromellose, magnesium stearate, and anhydrous lactose as inactive ingredients.
- AFINITOR DISPERZ ® tablets contain lactose monohydrate, crospovidone, butylated hydroxytoluene, hypromellose, magnesium stearate, colloidal silicon dioxide, mannitol, and microcrystalline cellulose as inactive ingredients.
- US5989591 claims a pharmaceutical composition of Everolimus which is a sugar- coated tablet comprising of sucrose and poloxamer. An inert core is coated with solid dispersion of above-mentioned ingredients.
- This prior-art relates to the conventional sugar-coated tablet and but not to the sublingual tablet. Further, this prior-art, wherein the drug is present in coating layer, has not disclosed any stability data as well as microbial data which indicate towards unsuccessful development of the stable dosage form which may be commercialized.
- W02000/033878 discloses pharmaceutical compositions of Everolimus that contains 0.2% (based on the weight of Everolimus) of antioxidant, preferably BFIT. Further, this prior-art relates to a conventional tablet and not to the sublingual tablet. This patent application was originally intended to prepare stabilized formulations of Everolimus; however, lack of stability data reporting in the patent application proves the said prior-art as an unstable one.
- W02003/028705 claims a pharmaceutical composition of Everolimus comprising a solid dispersion of Everolimus, a disintegrant and colloidal silicon dioxide, wherein the composition comprises 1 to 5% colloidal silicon dioxide by weight.
- the disintegration time reported in this prior-art for the above-mentioned composition is around 3 minutes, i.e. 90 seconds. Further, this prior-art relates to a dispersible tablet and not to the sublingual tablet. In addition, this patent application has not reported stability data which may indicate unsuccessful development of a stable dosage form.
- the inventors of the present invention also noted that presently marketed Everolimus formulations have very serious adverse effects including infection, asthenia, cough, fatigue, diarrhoea, anaemia, constipation, hypertension, hyperlipidaemia, nausea, mouth ulcer and mucositis.
- the inventors of the present invention felt that still, there is an unmet need to develop a dosage form of Everolimus, which overcome the drawbacks of prior available formulations, has good physical stability, is cost effective, can be produced by simple manufacturing techniques and can maximize the permeability of Everolimus from such dosage form and thereby improve its bioavailability with patient compliance.
- the principal object of the present invention is to provide novel sublingual pharmaceutical formulations of Everolimus and pharmaceutically acceptable salt thereof in the form of tablet which is to be placed under the tongue.
- the sublingual tablet provides better patient compliance; however, none of prior-arts teaches about sublingual formulations for Everolimus.
- Another prime objective of the present invention is to provide dose reduction of Everolimus with the sublingual route through bypassing first pass metabolism and thereby reducing excessive metabolism of Everolimus.
- Yet another object of the present invention is to provide synergistic formulations of Everolimus or pharmaceutically acceptable salt thereof along with one or more pharmaceutically acceptable excipients which are essential for synergistic effect.
- Another object of the present invention is to provide technically advanced patient- compliant dosage forms over existing dosage form and prior-arts.
- the other object of the present invention is to provide reduced dose Everolimus formulations and thereby reducing the cost of final formulations by providing an economic significant dosage form over existing dosage form and prior-arts.
- the present invention provides an oral composition of Everolimus preferably as a sublingual tablet form with pharmaceutically acceptable excipients and method of preparation thereof.
- the present invention establishes a very fast release of the pharmaceutical composition during initial dissolution owing to kind of excipients used in the formulation and thereby producing an immediate burst release which in turn immediate absorption of the drug into the blood stream. This action will help to increase bioavailability of Everolimus and pharmaceutically acceptable salt thereof in very short time.
- a pharmaceutical composition as per the present invention comprises Everolimus or pharmaceutically acceptable salt thereof.
- Everolimus is present in the form of free base, a pharmaceutically acceptable salt thereof, amorphous Everolimus, crystalline Everolimus, any isomer, derivative, hydrate, solvate or prodrug or a combination thereof.
- a synergistic pharmaceutical composition as per the present invention comprises several advantages including dose reduction, reduction in dose dependent side-effects and bypassing first pass metabolism of Everolimus in the liver.
- Embodiments of the pharmaceutical composition may include Everolimus as an active ingredient with one or more selected from pharmaceutically acceptable excipients like diluents, disintegrants, binders, lubricants, vehicles / solubility enhancing agents, stabilizers / anti-oxidants, suspending agents, permeability enhancers, preservatives, glidants, active carriers, anti-caking agents, wetting agents, preservatives, buffering agents and the like.
- pharmaceutically acceptable excipients like diluents, disintegrants, binders, lubricants, vehicles / solubility enhancing agents, stabilizers / anti-oxidants, suspending agents, permeability enhancers, preservatives, glidants, active carriers, anti-caking agents, wetting agents, preservatives, buffering agents and the like.
- composition in the form of sublingual tablets is prepared by wet granulation process comprising the steps of: (a) sifting one or more pharmaceutically acceptable excipients, (b) dissolving Everolimus and anti-oxidants in solvent and surfactant, (c) granulating the dry mix of step (a) with the drug solution of step (b) to obtain wet mass, (d) drying and sieving the wet mass to obtain granules, (e) blending the granules of step (d) with extra granular excipients if any, followed by lubrication and (f) compressing the lubricated blend of step (e) into tablets or filled into capsules.
- Everolimus the 40-O-(2-hydroxyethyl) derivative of rapamycin (sirolimus), is a potent and selective inhibitor of mechanistic target of rapamycin (mTOR).
- mTOR mechanistic target of rapamycin
- Everolimus is selective for the mTORCI protein complex.
- Everolimus exhibit potent immunosuppressive and anticancer activities.
- Everolimus is considered as BCS Class-Ill drug which have high solubility and low permeability.
- a pharmaceutical composition of Everolimus comprising of Everolimus as an active ingredient with pharmaceutically acceptable excipients.
- drug or “active ingredient” or “active pharmaceutical ingredient (API)” herein refers to Everolimus or a pharmaceutically acceptable salt thereof.
- Everolimus as used herein according to the present invention includes, Everolimus in the form of free base, a pharmaceutically acceptable salt thereof, amorphous Everolimus, crystalline Everolimus, any isomer, derivative, hydrate, solvate or prodrug or a combination thereof.
- drug solution includes solution obtained by dissolving Everolimus or its pharmaceutically acceptable salt thereof in solvent and (or) mixture of solvents.
- granulation includes, wet-granulation, dry-granulation or direct compression.
- pharmaceutically acceptable excipients refers to excipients those are routinely used in pharmaceutical compositions.
- the pharmaceutically acceptable excipients may comprise of diluents, disintegrants, binders, lubricants, vehicles / solubility enhancing agents, stabilizers / anti oxidants, suspending agents, permeability enhancers, preservatives, glidants, active carriers, anti-caking agents, wetting agents, preservatives, buffering agents and combinations thereof.
- Each excipient should be "acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the health of the patient.
- a wet granulation process for preparing stable sublingual compositions of Everolimus comprising the steps of: (a) sifting one or more pharmaceutically acceptable excipients, (b) dissolving Everolimus and anti-oxidants in solvent and surfactant, (c) granulating the dry mix of step (a) with the drug solution of step (b) to obtain wet mass, (d) drying and sieving the wet mass to obtain granules, (e) blending the granules of step (d) with extra granular excipients if any, followed by lubrication and (f) compressing the lubricated blend of step (e) into tablets or filled into capsules.
- the inventors of the present invention have invented such type of synergistic Everolimus sublingual dosage (with low dose of 3 mg) form which produces similar therapeutic effect as 10 mg of dosage form and thereby improving therapeutic efficacy of the present invention.
- solvents suitable for processing the pharmaceutical compositions include one or more of organic solvents such as organic solvents such as an alcohol, for example methanol, ethanol, or isopropanol; an ester, e.g. ethyl acetate; an ether, e.g. diethyl ether; a ketone, e.g. acetone; or a halogenated hydrocarbon, e.g. dichloroethane, dichloromethane (MDC) and the like.
- organic solvents such as an alcohol, for example methanol, ethanol, or isopropanol
- an ester e.g. ethyl acetate
- an ether e.g. diethyl ether
- a ketone e.g. acetone
- halogenated hydrocarbon e.g. dichloroethane, dichloromethane (MDC) and the like.
- the solvents may also include purified water.
- Suitable stabilizers or anti-oxidants may include but are not limited to one or more from butylated hydroxytoluene (BHT), Butylated hydroxy anisole (BHA), tocopherols (Vitamin E), scorbic acid (Vitamin C) or its derivatives, propyl gallate, sodium bisulphite, L-cysteine, magnesium bisulfite, sodium metabisulfite, ubiquinol, b-carotenes, uric acid, lipoic acid, thiourea, glutathione and fumaric acid and the like.
- BHT butylated hydroxytoluene
- BHA Butylated hydroxy anisole
- tocopherols Vitamin E
- scorbic acid Vitamin C or its derivatives
- propyl gallate sodium bisulphite, L-cysteine
- magnesium bisulfite sodium metabisulfite
- ubiquinol ubiquinol
- b-carotenes uric
- Suitable diluents, fillers, or bulking agents may include but are not limited to one or more from lactose, microcrystalline cellulose, reduced sugars such as monosaccharides like galactose, glucose, giyceraldehyde, fructose, ribose, and xylose; sugar alcohol such as mannitol, sorbitol, xylitol, lactitol, isomalt, maltitol and hydrogenated starch hydrolysates; dibasic calcium phosphate, calcium phosphate, powdered cellulose, calcium carbonate, magnesium carbonate, starch, pre gelatinized starch and the like.
- the inventors of the present invention used different diluents like Mannitol (Pearlitol 25C), Mannitol (Pearlitol 100 SD), F-Melt Type M, Prosolv Easytab SP, Prosolv Easytab SP - LM, PROSOLV ODT G2, Pharmaburst 500 and Dexrates (Emdex - Non-GMO).
- Prosolv Easytab SP contains mixture of Microcrystalline Cellulose (96%), Colloidal Silicon Dioxide (2%), Sodium Starch Glycolate (1.2%), Sodium Stearyl Fumarate (0.8%). Further, Prosolv Easytab SP - LM is low moisture grade lower moisture content ( ⁇ 3 %). Prosolv Easytab SP - LM was found to be suitable over other.
- the present invention comprises about 50-90% w/w of Prosolv Easytab SP of the total composition, preferably in the range of 65-75% w/w of Prosolv Easytab SP of the total composition.
- the inventors of the present invention surprisingly observed at the time of development of sub-lingual tablet that the diluent impacts disintegration (DT) time, tablet properties and impurity.
- the inventors of the present invention observed problems of Tablet DT and Tablet surface roughness and moisture uptake on storage.
- Suitable binders may include but are not limited to one or more from hydroxypropyl methylcellulose, hydroxypropyl cellulose, polyvinylpyrrolidone (povidone), gum arabic and sugars such as sucrose, glucose, dextrose, lactose, polyvinyl alcohol and the like.
- Suitable disintegrants may include but are not limited to one or more from crospovidone, croscarmellose sodium, starch, potato starch, pregelatinized starch, corn starch, sodium starch glycolate, microcrystalline cellulose, low substituted hydroxypropyl cellulose and the like.
- the present invention comprises about 5-25% w/w of disintegrants of the total composition, preferably in the range of 10-20% w/w of disintegrants of the total composition.
- the inventors of the present invention observed that disintegration time of Sodium starch glycolate was not achieved at different levels. Surprisingly, disintegration time of crospovidone was achieved with different grades and levels but the tablet surface was very rough. In addition, tablets made with crospovidone absorbed moisture and swelled. The inventors of the present invention noted that roughness on the tablet surface was observed due to the moisture absorption by crospovidone.
- Suitable wetting agents or surfactants or solubilizers may include but are not limited to one or more from the group comprising anionic, cationic, nonionic, or zwitterionic surfactants, or combinations thereof.
- wetting agents are sodium lauryl sulphate, cetrimide, polyethylene glycols, polyoxyethylene- polyoxypropylene block copolymers such as poloxamers, pluronic F68, polyglycerin fatty acid esters such as decaglyceryl monolaurate and decaglyceryl monomyristate, sorbitan fatty acid esters such as sorbitan monostearate, polyoxyethylene sorbitan fatty acid esters such as polyoxyethylene sorbitan monooleate, polyethylene glycol fatty acid esters such as polyoxyethylene monostearate, polyoxyethylene alkyl ethers such as polyoxyethylene lauryl ether, polyoxyethylene castor oil, sepitrap 80, polysorbate 80 and the like.
- the present invention comprises about
- SLS Lauryl Sulfate
- SEPITRAP 80 is a micro-encapsulated solubilizer in powder form designed to simplify the manufacturing of solid oral form drugs. It is manufactured by adsorption of the solubilizer in liquid form on a porous support. It contains Polysorbate 80 (45- 65%) adsorbed on Magnesium Alumino metasilicate (35-55%). The inventors of the present invention found Sepitrap 80 as beneficial because it helped to provide a better dissolution profile.
- Suitable lubricants may include but are not limited to one or more from fatty acids, fatty acid salts, and fatty acid esters such as magnesium stearate, calcium stearate, stearic acid, sodium stearyl fumarate, hydrogenated vegetable oil, colloidal silicon dioxide and mixtures thereof.
- the present invention comprises about 1 -15% w/w of lubricants of the total composition, preferably in the range of 1 -7% w/w of lubricants of the total composition.
- the inventors of the present invention surprisingly found that being water-soluble lubricant, Sodium stearyl fumarate provided better dissolution profile than water insoluble lubricants like Magnesium stearate.
- the inventors of the present invention observed that colloidal silicon dioxide improved wet granulation process. Hence, the combination of these inactive ingredients provided a synergistic effect.
- Suitable permeability enhancers may include but are not limited to one or more from the group comprising alcohols, Polyols, short-chain glycerides, amines, amides, cyclodextrins, fatty acids, pyrrolidines, azones, sulfoxides, surfactants, terpenes and the like.
- Suitable chelating or complexing agents may include but are not limited to one or more from the group comprising cyclodextrin, ethylenediamine tetra acetic acid or derivatives/salts thereof, e.g. disodium edetate, dihydroxyethyl glycine, glucamine, citric acid, tartaric acid, gluconic acid, phosphoric acid and the like.
- Suitable coloring and flavoring agents may include but are not limited to one or more from sucralose, maltose, orange flavor, vanilla flavor and the like. Being zero- calorie artificial flavoring agent, Sucralose was used in the formulation. Hence, the patients with diabetes can also take this medicine and thus, the present invention provided better patient compliance.
- the present invention comprises about less than 3% w/w of flavoring agents of the total composition, preferably less than 1% w/w of flavoring agents of the total composition.
- the inventors of the present invention also optimized the hardness of the tablet and disintegration time of the tablet by the selection of suitable punch tolling.
- the prime aspect of the present invention is that the pharmaceutical composition establishes a fast release pattern owing to the kind of excipients used in the formulation and thereby producing an immediate release that will in turn increase in bioavailability at initial release.
- a synergistic pharmaceutical composition as per the present invention comprises several advantages including dose reduction, reduction in dose dependent side-effects and bypassing first pass metabolism of Everolimus in the liver.
- One aspect of the present invention may include a pharmaceutical composition comprising about 0.1 mg to 20 mg of Everolimus with pharmaceutically acceptable excipients.
- the pharmaceutical composition manufactured is sublingual tablet, which results in to enhanced in-vitro dissolution profile.
- the formulated product manufactured is homogenous dispersions, which results in to enhanced in-vitro dissolution profile about 80% to 95% within initial 10 minutes of release.
- composition manufactured by number of stages in manufacturing process including mixing, wet-granulation and compression.
- formulated product is a stabilized sublingual tablet.
- process for preparation of an oral pharmaceutical composition as per the present invention comprising following steps:
- Lubrication 6. Adding and mixing of Crospovidone, sucralose, Sepitrap 80 to the dried and sized granules obtained in step-5;
- step-7 Compressing the lubricated blend obtained in step-7 to form tablets.
- EXAMPLE-1 Solvents do not remain in the finished product except in traces and are lost during processing.
- Lubrication 6. Crospovidone, sucralose, Sepitrap 80 were added to the dried and sized granules obtained in step-5 and mixed;
- EXAMPLE-2 Solvents do not remain in the finished product except in traces and are lost during processing. Similar manufacturing procedure was followed as per example-1 and results are reported in Test Example-2.
- EXAMPLE-3 Solvents do not remain in the finished product except in traces and are lost during processing.
- Ethanol and Dichloromethane (MDC) in 1 :1 ratio was taken and BHT was dissolved followed by addition of Poloxamer 188, Orange flavor and Everolimus.
- Granulation The granules were prepared using binder solution prepared in step-2 and blend of step-1. These granules were dried at 42 - 45°C until loss on drying (LOD) of granules at 105°C were attained less than 2.5%. Dried granules were sifted through 40# sieve. 4. Blending:
- Croscarmellose sodium, Sucralose and Sepitrap 80 were passed through 40# sieve and blended with dried-sized granules obtained in step-3.
- the inventors of the present invention observed that related impurities at 40°C / 75 % RH storage condition was higher. Hence, the inventors of the present invention checked related impurities at 30°C / 75 % RH storage condition and surprisingly found that impurities were drastically reduced. The inventors of the present invention hence now undergoing for studies at storage condition of 2-8°C.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to sublingual dosage forms of Everolimus and pharmaceutically acceptable salt thereof. The present invention also relates to provide patient-compliant, economical and technically advanced dosage form over existing marketed dosage form as well as nearest prior-arts which are mentioned in this patent application. Moreover, sublingual tablets of Everolimus prepared as per the present invention provide enhanced permeability and stability profile when compared to prior art inventions. Furthermore, the present invention also provides improved process which is relatively simple, easy to commercially manufacture, and functionally reproducible, thereby industrially applicable.
Description
“NOVEL SUBLINGUAL PHARMACEUTICAL FORMULATIONS FOR
EVEROLIMUS”
FIELD OF THE INVENTION:
The present invention relates to novel sublingual pharmaceutical formulations of Everolimus and pharmaceutically acceptable salt thereof. This present invention discloses sublingual tablet compositions of Everolimus and pharmaceutically acceptable salt thereof using one or more pharmaceutically acceptable excipients. Further, the present invention relates to providing an economical, patient compliant and technically advanced dosage form over existing dosage forms. In addition, the present invention shows industrial applicability in present industry infrastructure because it involves manufacturing of a tablet dosage form, which requires routine machineries.
BACKGROUND OF THE INVENTION:
Everolimus (CAS: 159351 -69-6) is a macrocyclic lactone that is rapamycin in which the hydroxy group attached to the cyclohexyl moiety has been converted into the corresponding 2-hydroxyethyl ether.
Everolimus is chemically known as (1 R,9S,12S,15R,16E,18R,19R,21 R,23S,24E, 26E,28E,30S,32S,35R)-1 ,18-dihydroxy- 12-{(1 R)-2-[(1 S,3R,4R)-4-(2-hydroxy- ethoxy)-3-methoxycyclohexyl]-1 -methylethyl}-19,30-dimethoxy-15,17,21 ,23,29, 35-hexamethyl-11 ,36-dioxa-4-aza-tricyclo[30.3.1 .0]hexatriaconta-16,24,26,28- tetraene-2,3,10,14,20-pentaone and is represented structurally as below:
EVEROLIMUS (I)
Everolimus, the 40-O-(2-hydroxyethyl) derivative of rapamycin (sirolimus), is a potent and selective inhibitor of mammalian target of rapamycin (mTOR). Everolimus is selective for the mTORCI protein complex. Everolimus exhibits potent immunosuppressive and anticancer activities. Everolimus is a white to beige colored powder with an empirical formula of C53FI83NO14 and the molecular weight is 958.2.
US5665772 discloses O-alkylated rapamycin derivatives which covers Everolimus for the first time. Everolimus is marketed as tablets (AFINITOR® and Zortress®), and tablets for oral suspension (AFINITOR DISPERZ®) by Novartis in USA. AFINITOR® tablets are approved by the United States Food and Drug Administration (USFDA) as anticancer agent in the treatment of advanced renal cell carcinoma (RCC) and subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis (TS). Zortress® tablets are approved by USFDA as immunosuppressant agent in the treatment of Prophylaxis of organ rejection in adult patients. Both AFINITOR® and Zortress® tablets contain lactose monohydrate, crospovidone, butylated hydroxytoluene (BFIT), hypromellose, magnesium stearate, and anhydrous lactose as inactive ingredients. AFINITOR DISPERZ® tablets contain lactose monohydrate, crospovidone, butylated hydroxytoluene, hypromellose, magnesium stearate, colloidal silicon dioxide, mannitol, and microcrystalline cellulose as inactive ingredients.
Innovator Brands in US Formulation Strengths available
AFINITOR® Oral Tablet 2.5 mg, 5 mg, 7.5 mg, 10 mg
ZORTRESS® Oral Tablet 0.25 mg, 0.5 mg, 0.75 mg, 1 mg
AFINITOR DISPERZ® Dispersible Tablet 2 mg, 3 mg, 5 mg From prior-art search results and as reported in Clinical Pharmacology and Biopharmaceutics review submitted for NDA 22-334, the inventors of the present invention are aware that Everolimus is considered as BCS Class-Ill drug which have high solubility and low permeability. Several approaches are reported to
overcome the problem of permeability and stability. Following are the nearest prior- arts to the present invention:
US5989591 claims a pharmaceutical composition of Everolimus which is a sugar- coated tablet comprising of sucrose and poloxamer. An inert core is coated with solid dispersion of above-mentioned ingredients. This prior-art relates to the conventional sugar-coated tablet and but not to the sublingual tablet. Further, this prior-art, wherein the drug is present in coating layer, has not disclosed any stability data as well as microbial data which indicate towards unsuccessful development of the stable dosage form which may be commercialized.
W02000/033878 discloses pharmaceutical compositions of Everolimus that contains 0.2% (based on the weight of Everolimus) of antioxidant, preferably BFIT. Further, this prior-art relates to a conventional tablet and not to the sublingual tablet. This patent application was originally intended to prepare stabilized formulations of Everolimus; however, lack of stability data reporting in the patent application proves the said prior-art as an unstable one.
W02003/028705 claims a pharmaceutical composition of Everolimus comprising a solid dispersion of Everolimus, a disintegrant and colloidal silicon dioxide, wherein the composition comprises 1 to 5% colloidal silicon dioxide by weight. The disintegration time reported in this prior-art for the above-mentioned composition is around 3 minutes, i.e. 90 seconds. Further, this prior-art relates to a dispersible tablet and not to the sublingual tablet. In addition, this patent application has not reported stability data which may indicate unsuccessful development of a stable dosage form.
Although the prior arts disclose different types of compositions which try to address the permeability and stability issues of Everolimus. Flowever, the inventors of the present invention could not find sufficient supported analytical data reported in these prior-arts that may prove Everolimus dosage form as stable one.
In addition, the inventors of the present invention also noted that presently marketed Everolimus formulations have very serious adverse effects including infection, asthenia, cough, fatigue, diarrhoea, anaemia, constipation, hypertension, hyperlipidaemia, nausea, mouth ulcer and mucositis.
Hence, the inventors of the present invention felt that still, there is an unmet need to develop a dosage form of Everolimus, which overcome the drawbacks of prior available formulations, has good physical stability, is cost effective, can be produced by simple manufacturing techniques and can maximize the permeability of Everolimus from such dosage form and thereby improve its bioavailability with patient compliance.
OBJECTIVES OF THE INVENTION:
The principal object of the present invention is to provide novel sublingual pharmaceutical formulations of Everolimus and pharmaceutically acceptable salt thereof in the form of tablet which is to be placed under the tongue. The sublingual tablet provides better patient compliance; however, none of prior-arts teaches about sublingual formulations for Everolimus.
Another prime objective of the present invention is to provide dose reduction of Everolimus with the sublingual route through bypassing first pass metabolism and thereby reducing excessive metabolism of Everolimus.
Yet another object of the present invention is to provide synergistic formulations of Everolimus or pharmaceutically acceptable salt thereof along with one or more pharmaceutically acceptable excipients which are essential for synergistic effect.
Another object of the present invention is to provide technically advanced patient- compliant dosage forms over existing dosage form and prior-arts.
The other object of the present invention is to provide reduced dose Everolimus formulations and thereby reducing the cost of final formulations by providing an economic significant dosage form over existing dosage form and prior-arts.
One more object of the present invention is to provide a process for preparation of sublingual formulations of Everolimus and pharmaceutically acceptable salt thereof using one or more pharmaceutically acceptable excipients in the form of a tablet which is to be placed under the tongue. Prior-arts fail to disclose about such tablets which are sublingual for Everolimus.
Yet another objective of the present invention is to provide sublingual formulations of Everolimus and one or more pharmaceutically acceptable excipients with longer stability profile. SUMMARY OF THE INVENTION:
Despite of extensive research on Everolimus as reported in prior-art publications, there is an unmet need to develop a patient compliant oral sublingual composition for Everolimus with technical advancement which provide fast dissolution for immediate action as well as good stability for long-term storage. This dosage form also increases patient compliance because patient feels difficulty in taking conventional tablet or dispersible tablets when he or she is outdoor; whereas sublingual tablet does not require even water. Thus, the present invention has solved the problem that is present in the prior-arts as well as in the existing marketed formulations. Accordingly, the present invention provides an oral composition of Everolimus preferably as a sublingual tablet form with pharmaceutically acceptable excipients and method of preparation thereof.
The present invention establishes a very fast release of the pharmaceutical composition during initial dissolution owing to kind of excipients used in the formulation and thereby producing an immediate burst release which in turn immediate absorption of the drug into the blood stream. This action will help to increase bioavailability of Everolimus and pharmaceutically acceptable salt thereof in very short time.
In another general embodiment of the present invention, a pharmaceutical composition as per the present invention comprises Everolimus or pharmaceutically acceptable salt thereof. Preferably, Everolimus is present in the form of free base, a pharmaceutically acceptable salt thereof, amorphous Everolimus, crystalline Everolimus, any isomer, derivative, hydrate, solvate or prodrug or a combination thereof.
In another embodiment of the present invention, a synergistic pharmaceutical composition as per the present invention comprises several advantages including dose reduction, reduction in dose dependent side-effects and bypassing first pass metabolism of Everolimus in the liver.
Embodiments of the pharmaceutical composition may include Everolimus as an active ingredient with one or more selected from pharmaceutically acceptable excipients like diluents, disintegrants, binders, lubricants, vehicles / solubility enhancing agents, stabilizers / anti-oxidants, suspending agents, permeability enhancers, preservatives, glidants, active carriers, anti-caking agents, wetting agents, preservatives, buffering agents and the like.
In another embodiment of the present invention, pharmaceutical composition is in the form of sublingual tablets is prepared by wet granulation process comprising the steps of: (a) sifting one or more pharmaceutically acceptable excipients, (b) dissolving Everolimus and anti-oxidants in solvent and surfactant, (c) granulating the dry mix of step (a) with the drug solution of step (b) to obtain wet mass, (d) drying and sieving the wet mass to obtain granules, (e) blending the granules of step (d) with extra granular excipients if any, followed by lubrication and (f) compressing the lubricated blend of step (e) into tablets or filled into capsules.
The details of one or more embodiments of the invention are set forth in the description below. Other features of the invention will be apparent from the description.
DETAILED DESCRIPTION OF THE INVENTION:
The following detailed description of the present subject matter the various embodiments. These embodiments are described in sufficient detail to enable those skilled in the art to practice the present subject matter. Other embodiments may be utilized and structural, logical, and electrical changes may be made without departing from the scope of the present subject matter.
References to “an”, “one”, or “various” embodiments in this disclosure are not necessarily to the same embodiment, and such references contemplate more than
one embodiment. The following detailed description is, therefore, not to be taken in a limiting sense, and the scope is defined only by the appended claims, along with the full scope of legal equivalents to which such claims are entitled.
Everolimus, the 40-O-(2-hydroxyethyl) derivative of rapamycin (sirolimus), is a potent and selective inhibitor of mechanistic target of rapamycin (mTOR). Everolimus is selective for the mTORCI protein complex. Everolimus exhibit potent immunosuppressive and anticancer activities. Everolimus is considered as BCS Class-Ill drug which have high solubility and low permeability.
In accordance with the present invention, a pharmaceutical composition of Everolimus comprising of Everolimus as an active ingredient with pharmaceutically acceptable excipients.
The term "drug" or “active ingredient” or “active pharmaceutical ingredient (API)” herein refers to Everolimus or a pharmaceutically acceptable salt thereof.
The term "Everolimus" as used herein according to the present invention includes, Everolimus in the form of free base, a pharmaceutically acceptable salt thereof, amorphous Everolimus, crystalline Everolimus, any isomer, derivative, hydrate, solvate or prodrug or a combination thereof.
The term "drug solution" as used herein according to the present invention includes solution obtained by dissolving Everolimus or its pharmaceutically acceptable salt thereof in solvent and (or) mixture of solvents.
The term "granulation" as used herein according to the present invention includes, wet-granulation, dry-granulation or direct compression.
The term "pharmaceutically acceptable excipients" as used herein, refers to excipients those are routinely used in pharmaceutical compositions. The pharmaceutically acceptable excipients may comprise of diluents, disintegrants, binders, lubricants, vehicles / solubility enhancing agents, stabilizers / anti oxidants, suspending agents, permeability enhancers, preservatives, glidants, active carriers, anti-caking agents, wetting agents, preservatives, buffering agents and combinations thereof. Each excipient should be "acceptable" in the sense of
being compatible with the other ingredients of the formulation and not injurious to the health of the patient.
In accordance with the present invention, it provides a wet granulation process for preparing stable sublingual compositions of Everolimus comprising the steps of: (a) sifting one or more pharmaceutically acceptable excipients, (b) dissolving Everolimus and anti-oxidants in solvent and surfactant, (c) granulating the dry mix of step (a) with the drug solution of step (b) to obtain wet mass, (d) drying and sieving the wet mass to obtain granules, (e) blending the granules of step (d) with extra granular excipients if any, followed by lubrication and (f) compressing the lubricated blend of step (e) into tablets or filled into capsules.
The inventors of the present invention have invented such type of synergistic Everolimus sublingual dosage (with low dose of 3 mg) form which produces similar therapeutic effect as 10 mg of dosage form and thereby improving therapeutic efficacy of the present invention.
According to the present invention, solvents suitable for processing the pharmaceutical compositions include one or more of organic solvents such as organic solvents such as an alcohol, for example methanol, ethanol, or isopropanol; an ester, e.g. ethyl acetate; an ether, e.g. diethyl ether; a ketone, e.g. acetone; or a halogenated hydrocarbon, e.g. dichloroethane, dichloromethane (MDC) and the like. The solvents may also include purified water.
Suitable stabilizers or anti-oxidants may include but are not limited to one or more from butylated hydroxytoluene (BHT), Butylated hydroxy anisole (BHA), tocopherols (Vitamin E), scorbic acid (Vitamin C) or its derivatives, propyl gallate, sodium bisulphite, L-cysteine, magnesium bisulfite, sodium metabisulfite, ubiquinol, b-carotenes, uric acid, lipoic acid, thiourea, glutathione and fumaric acid and the like. The inventors of the present invention surprisingly found that BHT provided better stability than other anti-oxidants. The present invention comprises about 1 -5% w/w of anti-oxidants of the total composition, preferably in the range of 1 -3% w/w of anti-oxidants of the total composition.
Suitable diluents, fillers, or bulking agents may include but are not limited to one or more from lactose, microcrystalline cellulose, reduced sugars such as
monosaccharides like galactose, glucose, giyceraldehyde, fructose, ribose, and xylose; sugar alcohol such as mannitol, sorbitol, xylitol, lactitol, isomalt, maltitol and hydrogenated starch hydrolysates; dibasic calcium phosphate, calcium phosphate, powdered cellulose, calcium carbonate, magnesium carbonate, starch, pre gelatinized starch and the like.
The inventors of the present invention used different diluents like Mannitol (Pearlitol 25C), Mannitol (Pearlitol 100 SD), F-Melt Type M, Prosolv Easytab SP, Prosolv Easytab SP - LM, PROSOLV ODT G2, Pharmaburst 500 and Dexrates (Emdex - Non-GMO).
Among these, Prosolv Easytab SP contains mixture of Microcrystalline Cellulose (96%), Colloidal Silicon Dioxide (2%), Sodium Starch Glycolate (1.2%), Sodium Stearyl Fumarate (0.8%). Further, Prosolv Easytab SP - LM is low moisture grade lower moisture content (< 3 %). Prosolv Easytab SP - LM was found to be suitable over other. The present invention comprises about 50-90% w/w of Prosolv Easytab SP of the total composition, preferably in the range of 65-75% w/w of Prosolv Easytab SP of the total composition.
The inventors of the present invention surprisingly observed at the time of development of sub-lingual tablet that the diluent impacts disintegration (DT) time, tablet properties and impurity. The inventors of the present invention observed problems of Tablet DT and Tablet surface roughness and moisture uptake on storage.
Suitable binders may include but are not limited to one or more from hydroxypropyl methylcellulose, hydroxypropyl cellulose, polyvinylpyrrolidone (povidone), gum arabic and sugars such as sucrose, glucose, dextrose, lactose, polyvinyl alcohol and the like.
Suitable disintegrants may include but are not limited to one or more from crospovidone, croscarmellose sodium, starch, potato starch, pregelatinized starch, corn starch, sodium starch glycolate, microcrystalline cellulose, low substituted hydroxypropyl cellulose and the like. The present invention comprises about 5-25% w/w of disintegrants of the total composition, preferably in the range of 10-20% w/w of disintegrants of the total composition.
The inventors of the present invention observed that disintegration time of Sodium starch glycolate was not achieved at different levels. Surprisingly, disintegration time of crospovidone was achieved with different grades and levels but the tablet surface was very rough. In addition, tablets made with crospovidone absorbed moisture and swelled. The inventors of the present invention noted that roughness on the tablet surface was observed due to the moisture absorption by crospovidone.
Surprisingly, when the inventors of the present invention combined Prosolv Easytab SP - LM in optimum concentration in combination with croscarmellose sodium, the rough surface tablet problem was solved and optimum disintegration time was also achieved. Thus, synergistic effect was observed by the inventors of the present invention by combining these two inactive ingredients. In addition, this excipient combination also provided rapid dissolution which is prime requirement of sub-lingual route. Furthermore, this combination of excipients also improved mouthfeel than other excipients which is also the requirement for the sub-lingual route.
Suitable wetting agents or surfactants or solubilizers may include but are not limited to one or more from the group comprising anionic, cationic, nonionic, or zwitterionic surfactants, or combinations thereof. Suitable examples of wetting agents are sodium lauryl sulphate, cetrimide, polyethylene glycols, polyoxyethylene- polyoxypropylene block copolymers such as poloxamers, pluronic F68, polyglycerin fatty acid esters such as decaglyceryl monolaurate and decaglyceryl monomyristate, sorbitan fatty acid esters such as sorbitan monostearate, polyoxyethylene sorbitan fatty acid esters such as polyoxyethylene sorbitan monooleate, polyethylene glycol fatty acid esters such as polyoxyethylene monostearate, polyoxyethylene alkyl ethers such as polyoxyethylene lauryl ether, polyoxyethylene castor oil, sepitrap 80, polysorbate 80 and the like. The present invention comprises about 5-20% w/w of solubilizers of the total composition, preferably in the range of 1 -15% w/w of solubilizers of the total composition.
The inventors of the present invention surprisingly found that Sodium Lauryl Sulfate [SLS] (brand: Kolliphor SLS Fine, Kolliphor P188) improved dissolution in different dissolution media. Flence, it shows that the final formulation is showing the same
dissolution nature in any pH of the dissolution media and hence, is more stable in releasing profile.
SEPITRAP 80 is a micro-encapsulated solubilizer in powder form designed to simplify the manufacturing of solid oral form drugs. It is manufactured by adsorption of the solubilizer in liquid form on a porous support. It contains Polysorbate 80 (45- 65%) adsorbed on Magnesium Alumino metasilicate (35-55%). The inventors of the present invention found Sepitrap 80 as beneficial because it helped to provide a better dissolution profile.
Suitable lubricants may include but are not limited to one or more from fatty acids, fatty acid salts, and fatty acid esters such as magnesium stearate, calcium stearate, stearic acid, sodium stearyl fumarate, hydrogenated vegetable oil, colloidal silicon dioxide and mixtures thereof. The present invention comprises about 1 -15% w/w of lubricants of the total composition, preferably in the range of 1 -7% w/w of lubricants of the total composition.
The inventors of the present invention surprisingly found that being water-soluble lubricant, Sodium stearyl fumarate provided better dissolution profile than water insoluble lubricants like Magnesium stearate. In addition, the inventors of the present invention observed that colloidal silicon dioxide improved wet granulation process. Hence, the combination of these inactive ingredients provided a synergistic effect.
Suitable permeability enhancers may include but are not limited to one or more from the group comprising alcohols, Polyols, short-chain glycerides, amines, amides, cyclodextrins, fatty acids, pyrrolidines, azones, sulfoxides, surfactants, terpenes and the like.
Suitable chelating or complexing agents may include but are not limited to one or more from the group comprising cyclodextrin, ethylenediamine tetra acetic acid or derivatives/salts thereof, e.g. disodium edetate, dihydroxyethyl glycine, glucamine, citric acid, tartaric acid, gluconic acid, phosphoric acid and the like.
Suitable coloring and flavoring agents may include but are not limited to one or more from sucralose, maltose, orange flavor, vanilla flavor and the like. Being zero- calorie artificial flavoring agent, Sucralose was used in the formulation. Hence, the
patients with diabetes can also take this medicine and thus, the present invention provided better patient compliance. The present invention comprises about less than 3% w/w of flavoring agents of the total composition, preferably less than 1% w/w of flavoring agents of the total composition. The inventors of the present invention also optimized the hardness of the tablet and disintegration time of the tablet by the selection of suitable punch tolling.
The prime aspect of the present invention is that the pharmaceutical composition establishes a fast release pattern owing to the kind of excipients used in the formulation and thereby producing an immediate release that will in turn increase in bioavailability at initial release.
In another aspect of the present invention, a synergistic pharmaceutical composition as per the present invention comprises several advantages including dose reduction, reduction in dose dependent side-effects and bypassing first pass metabolism of Everolimus in the liver. One aspect of the present invention may include a pharmaceutical composition comprising about 0.1 mg to 20 mg of Everolimus with pharmaceutically acceptable excipients.
In yet another aspect of the present invention, wherein the pharmaceutical composition manufactured is sublingual tablet, which results in to enhanced in-vitro dissolution profile.
Another aspect according to the present invention, wherein the formulated product manufactured is homogenous dispersions, which results in to enhanced in-vitro dissolution profile about 80% to 95% within initial 10 minutes of release.
In yet another aspect of the present invention, wherein the pharmaceutical composition manufactured by number of stages in manufacturing process including mixing, wet-granulation and compression.
Additional aspect according to the present invention is that the formulated product is a stabilized sublingual tablet.
In one aspect process for preparation of an oral pharmaceutical composition as per the present invention comprising following steps:
1. Co-milling of Mannitol, crospovidone and colloidal silicon dioxide through #30 sieve; Binder solution preparation:
2. Mixing of ethanol and water were followed by addition of BFIT, Poloxamer 188 and orange flavour;
3. Dissolving Everolimus in to the solution obtained in step-2 to prepare the binder solution; Granulation:
4. Geometrically mixing of dry mix blend obtained in step-1 in slow manner to the binder solution obtained in step-3;
5. Drying and sifting of wet-granules obtained in stape-4;
Lubrication: 6. Adding and mixing of Crospovidone, sucralose, Sepitrap 80 to the dried and sized granules obtained in step-5;
7. Lubricating the blend obtained in step-6 with magnesium stearate;
Compression:
8. Compressing the lubricated blend obtained in step-7 to form tablets.
The invention will be further described with respect to the following examples; however, the scope of the invention is not limited thereby. While the present invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention.
EXAMPLES:
Following section now will describe various formulation example as well as test examples by which the formulation example were evaluated. Further, results of the
present invention were compared with the marketed formulation as well as nearest prior-arts.
EXAMPLE-1 :
Solvents do not remain in the finished product except in traces and are lost during processing.
Process for preparation:
1 . Mannitol, crospovidone and colloidal silicon dioxide were co-sifted through #30 sieve; Binder solution preparation:
2. Ethanol and water were mixed followed by addition of BHT, Poloxamer 188 and orange flavour;
3. Everolimus was dissolved in to the solution obtained in step-2 to prepare the binder solution; Granulation:
4. Dry mix blend obtained in step-1 was geometrically mixed in slow manner to the binder solution obtained in step-3;
5. Wet-granules obtained in stape-4 were dried and sifted through #30 sieve;
Lubrication: 6. Crospovidone, sucralose, Sepitrap 80 were added to the dried and sized granules obtained in step-5 and mixed;
7. Magnesium stearate was added to the blend obtained in step-6 for the lubrication;
Compression: 8. Lubricated blend obtained in step-7 was compressed to form tablets.
EXAMPLE-2:
Solvents do not remain in the finished product except in traces and are lost during processing.
Similar manufacturing procedure was followed as per example-1 and results are reported in Test Example-2.
EXAMPLE-3:
Solvents do not remain in the finished product except in traces and are lost during processing.
Process for preparation:
1. Prosolv easy Tab SP- LM, SLS (Kolliphor SLS Fine), and colloidal silicon dioxide were shifted through 40# Sieve. 2. Binder Solution:
Ethanol and Dichloromethane (MDC) in 1 :1 ratio was taken and BHT was dissolved followed by addition of Poloxamer 188, Orange flavor and Everolimus.
3. Granulation:
The granules were prepared using binder solution prepared in step-2 and blend of step-1. These granules were dried at 42 - 45°C until loss on drying (LOD) of granules at 105°C were attained less than 2.5%. Dried granules were sifted through 40# sieve. 4. Blending:
Croscarmellose sodium, Sucralose and Sepitrap 80 were passed through 40# sieve and blended with dried-sized granules obtained in step-3.
5. Lubrication:
Sodium Stearyl Fumarate was sifted through 60 # sieve for 5 minutes and added to the blend of step-4.
6. Compression:
The lubricated blend obtained in step-5 was compressed sing 6 mm size punch tooling. TEST EXAMPLE-1 : Dissolution Profile comparison
Comparison of the dissolution profile study was incorporated to evaluate the comparative dissolution profile of the composition prepared in Example-1.
For this comparative study, dissolution profile in two different dissolution media was performed. One Media taken was Water with 0.4% Sodium dodecyl sulfate (SDS) and the other was pH 6.8 Phosphate buffer with 0.4% SDS. Both having 900 ml volume of in USP apparatus type II (paddle) at 50 RPM at 37°C. The obtained dissolution profile results are reported in the table-2.
TEST EXAMPLE-2: ANALYTICAL EVALUATION FOR EXAMPLE-2
Following are the analytical evaluation data for example-2 with stability study which includes assay, water content and related substance.
The inventors of the present invention observed that related impurities at 40°C / 75 % RH storage condition was higher. Hence, the inventors of the present invention checked related impurities at 30°C / 75 % RH storage condition and surprisingly found that impurities were drastically reduced. The inventors of the present invention hence now undergoing for studies at storage condition of 2-8°C.
TEST EXAMPLE-3: ANALYTICAL EVALUATION FOR EXAMPLE-3
Following are the analytical evaluation data for example-3 with stability study which includes assay, related substance and dissolution studies.
The invention described herein comprises in various objects as mentioned above and their description in relation to characteristics, compositions and process adopted. While these aspects are emphasised in the invention, any variations of the invention described above are not to be regarded as departure from the spirit and scope of the invention as described.
The above-mentioned examples are provided for illustrative purpose only and these examples are in no way limitative on the present invention.
Claims
1. A sublingual pharmaceutical composition of Everolimus comprising: a. 60-70% w/w of Prosolv Easytab SP, and b. 10-20% w/w of one or more disintegrants
2. The sublingual pharmaceutical composition of Everolimus as claimed in claim-1 , wherein one or more disintegrants are selected from croscarmellose sodium, sodium stearyl fumarate or combination thereof.
3. The sublingual pharmaceutical composition of Everolimus as claimed in claim-1 , wherein the composition further essentially comprises lubricant in the concentration range of 1 -5% w/w of the total composition.
4. The sublingual pharmaceutical composition of Everolimus as claimed in claim-3, wherein the composition further essentially comprises lubricant is sodium stearyl fumarate.
5. The sublingual pharmaceutical composition of Everolimus as claimed in claim-1 , wherein the composition further comprises solubilizers in the concentration range of 1-10% w/w of the total composition.
6. The sublingual pharmaceutical composition of Everolimus as claimed in claim-5, wherein the composition further essentially comprises solubilizers selected from poloxamer 188, sodium lauryl sulphate, sepitrap 80 or combination thereof.
7. The sublingual pharmaceutical composition of Everolimus as claimed in claim-1 , wherein the composition further comprises anti-oxidant in the concentration range of 1 -3% w/w of the total composition, wherein the anti oxidant is butylated hydroxy toluene.
8. The sublingual pharmaceutical composition of Everolimus as claimed in claim-1 , wherein the composition further comprises flavouring agents in the
concentration less than 1% w/w of the total composition, wherein the flavouring agents is sucralose.
9. The sublingual pharmaceutical composition of Everolimus as claimed in claim-1 , wherein the composition may further comprises colloidal silicon dioxide.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN202121017850 | 2021-04-17 | ||
IN202121017850 | 2021-04-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022219652A1 true WO2022219652A1 (en) | 2022-10-20 |
Family
ID=83639853
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2022/050364 WO2022219652A1 (en) | 2021-04-17 | 2022-04-16 | Novel sublingual pharmaceutical formulations for everolimus |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2022219652A1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1561201A (en) * | 2001-09-28 | 2005-01-05 | 诺瓦提斯公司 | Pharmaceutical compositions comprising colloidal silicon dioxide |
US20140242162A1 (en) * | 2011-10-06 | 2014-08-28 | Novartis Ag | Pharmaceutical compositions comprising 40 - o - ( 2 - hydroxy) ethyl - rapamycin |
-
2022
- 2022-04-16 WO PCT/IN2022/050364 patent/WO2022219652A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1561201A (en) * | 2001-09-28 | 2005-01-05 | 诺瓦提斯公司 | Pharmaceutical compositions comprising colloidal silicon dioxide |
US20140242162A1 (en) * | 2011-10-06 | 2014-08-28 | Novartis Ag | Pharmaceutical compositions comprising 40 - o - ( 2 - hydroxy) ethyl - rapamycin |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6645526B2 (en) | Storage stable thyroxine active drug formulations and methods for their production | |
KR101632079B1 (en) | Pharmaceutical composition containing dihydropyridine calcium channel antagonist and method for the preparation thereof | |
RU2401109C2 (en) | Tablet-form slow-release preparation for vertigo | |
US20080305158A1 (en) | Methods For the Preparation of Stable Pharmaceutical Solid Dosage Forms of Atorvastatin and Amlodipine | |
JP2012510483A5 (en) | ||
JP2012525427A (en) | Clavulanate formulation for neuroprotection and treatment of neurodegenerative diseases | |
EA027869B1 (en) | Stabilized tacrolimus composition | |
WO2008048802A1 (en) | Phenylalkyl carbamate compositions | |
AU2024216408A1 (en) | Improved bromocriptine formulations | |
US7052717B2 (en) | Storage stable thyroxine active drug formulations and methods for their production | |
AU2022256110A1 (en) | Hsp90 inhibitor oral formulations and related methods | |
JP2023507787A (en) | Compositions with improved solubility and bioavailability of olaparib | |
US20020123503A1 (en) | Cabergoline pharmaceutical compositions and methods of use thereof | |
US20100086590A1 (en) | Novel stable pharmaceutical compositions of clopidogrel bisulfate and process of preparation thereof | |
JPH1192369A (en) | Pharmaceutical preparation, its production and use of acidic additive for stabilization of cilansetron | |
WO2022219652A1 (en) | Novel sublingual pharmaceutical formulations for everolimus | |
EP3219309A1 (en) | Fixed dosed pharmaceutical composition comprising amlodipine, candesartan cilexetil and hydrochlorothiazide for the treatment of hypertension | |
WO2013168032A1 (en) | Pharmaceutical compositions comprising rasagiline | |
CN116600827A (en) | Olaparib solid dispersion compositions with improved stability and bioavailability | |
EP1560568B1 (en) | Controlled release pharmaceutical compositions containing sodium alginate and sodium calcium alginate | |
EP4180042A1 (en) | A film coated tablet comprising micronized tofacitinib | |
CN111683659B (en) | Composition of amino pyran derivative | |
WO2011086577A2 (en) | Pharmaceutical composition of moxifloxacin and its pharmaceutically acceptable salts | |
WO2023086066A1 (en) | A film coated tablet comprising micronized tofacitinib | |
US20220175774A1 (en) | Bioavailable Oral Dosage Form Of Tyrosine-Kinase Inhibitor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22787782 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22787782 Country of ref document: EP Kind code of ref document: A1 |